When Does Lynparza Patent Expire?

Lynparza's earliest patent expiration is in 2028, roughly 2.3 years out. That places this drug in the medium-term cliff window — most pharmaceutical analysts begin modeling generic erosion 3 to 5 years before the first composition-of-matter expiry, because that is when the FDA's 30-month stay clock starts ticking after the first ANDA filing. Latest portfolio expiration: 2042.

Because Lynparza's patent cliff is within three years, generic manufacturers are likely already preparing ANDA filings or have filed Paragraph IV certifications. Under Hatch-Waxman, the first successful Paragraph IV challenger earns a 180-day exclusivity period as the sole generic. Watch FDA's Paragraph IV certification list for filing activity tied to Lynparza.

For the authoritative listing of patents tied to a specific drug — the patents an ANDA filer is legally required to address under 21 USC § 355(j) — consult the FDA Orange Book. Underlying utility patent data on this page is sourced from USPTO PatentsView, the federal government's free public patent API.

Lynparza is protected by 16 US patents — a large portfolio that signals an aggressive lifecycle management strategy. Mega-portfolios of 15+ patents are characteristic of top-selling drugs (Humira famously had over 130) where the manufacturer has built layered protection across composition, multiple formulations, dosing schedules, drug-device combinations, and method-of-use claims for individual indications. These layered portfolios typically face Paragraph IV litigation under the Hatch-Waxman framework as generic challengers test secondary patents one by one.

All 16 patents in the Lynparza portfolio are assigned to AstraZeneca AB, indicating consolidated ownership. Single-assignee portfolios are simpler to litigate and easier to license — generic challengers face one negotiating counterparty, and any settlement or pay-for-delay arrangement involves only that holder.

The Lynparza portfolio scores 40/100 (Grade D, "weak") on the PatentCliff Strength index. The strongest signal is claims breadth (67/100), and the weakest is technology diversity (10/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.

Looking at the 16 dated patents in the portfolio, the largest cluster (5 patents) falls in the "Beyond 2036" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.

The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.